Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT07462377

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Led by EpiBiologics · Updated on 2026-05-08

110

Participants Needed

6

Research Sites

169 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

CONDITIONS

Official Title

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant has a life expectancy greater than 12 weeks at Day 1
  • Participant has an ECOG performance status of 0-2
  • Participant has pathologically confirmed NSCLC or HNSCC
  • For NSCLC: tumor harbors any documented EGFR mutation, insertion, or deletion
  • Participant has locally advanced or metastatic NSCLC or HNSCC
  • Participant has adequate organ function
Not Eligible

You will not qualify if you...

  • Participant has a history of uncontrolled illness
  • Participant has symptomatic brain metastases
  • Participant has a diagnosis of any secondary malignancy within 3 years prior to enrollment, except for those treated with curative intent and no evidence of active disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

START Los Angeles

Los Angeles, California, United States, 90025

Actively Recruiting

2

Astera Cancer Care

East Brunswick, New Jersey, United States, 08816

Actively Recruiting

3

START New York Long Island

Lake Success, New York, United States, 11042

Not Yet Recruiting

4

Sarah Cannon and HCA Research Institute

Nashville, Tennessee, United States, 37203

Actively Recruiting

5

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Not Yet Recruiting

6

South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, United States, 78229

Actively Recruiting

Loading map...

Research Team

E

EpiBiologics Clinical Trials

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | DecenTrialz